Pilot Study – Use of [68Ga] gallium-labelled Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) for the Characterisation of Metastatic Lesions in Patients with Renal Cell Carcinoma

Trial Profile

Pilot Study – Use of [68Ga] gallium-labelled Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) for the Characterisation of Metastatic Lesions in Patients with Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Renal cell carcinoma
  • Focus Diagnostic use
  • Most Recent Events

    • 20 Jul 2016 Status changed from recruiting to completed.
    • 17 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top